Cantor Fitzgerald Reaffirms “Overweight” Rating for Alumis (NASDAQ:ALMS)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Alumis (NASDAQ:ALMS) in a report published on Thursday,Benzinga reports.

Other analysts also recently issued reports about the company. Oppenheimer started coverage on Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 target price (down from $19.00) on shares of Alumis in a research report on Thursday. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Stock Performance

Shares of ALMS opened at $3.75 on Thursday. The business has a fifty day moving average of $5.69 and a 200 day moving average of $8.56. Alumis has a 52-week low of $3.18 and a 52-week high of $13.53.

Institutional Trading of Alumis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new position in shares of Alumis during the third quarter valued at $3,266,000. State Street Corp purchased a new position in shares of Alumis during the third quarter valued at $866,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Alumis during the third quarter valued at $1,160,000. Stifel Financial Corp purchased a new position in shares of Alumis during the third quarter valued at $931,000. Finally, Barclays PLC purchased a new position in shares of Alumis during the third quarter valued at $197,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.